Figure 3.

Genetic Interactions Related to Drug Response in Tissue-Specific Cell Lines

(A and B) Consistency ratio of (A) SV interactions related to drug resistance and (B) SL interactions related to drug sensitivity of four drugs (p < 0.05, Wilcoxon rank-sum test, white; and p < 0.01, Wilcoxon rank-sum test, black) in CCLE, CTRP, and GDSC datasets. Dark purple indicates a higher consistency ratio, and grids lacking purple indicate no detection. Different colors represent different tissues. The blank grid indicates that the consistency ratio cannot be tested because of a limited number of cell lines. (C) Consistency ratio of erlotinib in lung cancer tissue. (D–G) Cell lines with EGFR amplification or mutation are sensitive to the ERBB2-related drug, erlotinib, in CCLE, CTRP, and GDSC (AUC, LN_IC₅₀) datasets (Wilcoxon rank-sum test). (D) IC₅₀ of erlotinib in CCLE. (E) AUC of erlotinib in CTRP. (F) AUC of erlotinib in GDSC. (G) LN_IC₅₀ of erlotinib in GDSC.